Liraglutide vs Semaglutide vs Dulaglutide in Veterans With Type 2 Diabetes

Are different glucagon-like peptide-1 receptor agonists associated with differences in kidney and cardiovascular outcomes among patients with type 2 diabetes?In this comparative effectiveness study of 21 790 veterans with type 2 diabetes and without end-stage kidney disease, kidney and cardiovascular outcomes were similar among liraglutide, semaglutide, and dulaglutide initiators.These findings highlight the need for head-to-head randomized clinical trials to definitively establish potential differences among glucagon-like peptide-1 receptor agonists.

Corresponding Author: Srinivasan Beddhu, MD, Division of Nephrology and Hypertension, University of Utah School of Medicine, 421 Wakara Way, Room 360, Salt Lake City, UT 84108 (srinivasan.beddhu@hsc.utah.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.